FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792740135> ?p ?o ?g. }

• W2792740135 endingPage "469" @default.
• W2792740135 startingPage "462" @default.
• W2792740135 abstract "The study sought to evaluate for the first time the 5-year outcomes after treating an all-comers population with newer-generation cobalt chromium-based Resolute Integrity zotarolimus-eluting stents (ZES) (Medtronic, Santa Rosa, California) versus platinum chromium-based PROMUS Element everolimus eluting stents (EES) (Boston Scientific, Natick, Massachusetts).The DUTCH PEERS (TWENTE II) (DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity: TWENTE II) trial is a randomized, multicenter, single-blinded, investigator-initiated all-comers trial that found at its main analysis similar 1-year safety and efficacy for both drug-eluting stents. It is the first randomized trial ever to investigate the Resolute Integrity ZES and the first trial to compare both devices.In total, 1,811 patients were 1:1 randomized to ZES versus EES. We performed a pre-specified assessment of the 5-year clinical outcomes in terms of safety and efficacy. The main endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization. Secondary endpoints included the individual components of TVF, and stent thrombosis. The study was independently monitored, and adverse clinical events were independently adjudicated.Five-year clinical follow-up data was available in 1,798 (99.3%) patients. The ZES and EES groups showed favorable outcomes, with similar 5-year incidence of TVF (13.2% vs. 14.2%; plog-rank = 0.62) and its individual components: cardiac death (4.5% vs. 4.9%; plog-rank = 0.69), target vessel-related myocardial infarction (3.1% vs. 2.6%; plog-rank = 0.47), and target vessel revascularization (7.6% vs. 8.6%; plog-rank = 0.46). The 5-year incidence of definite or probable stent thrombosis was similar (1.5% vs. 1.3%; plog-rank = 0.83).At 5-year follow-up, the Resolute Integrity ZES and PROMUS Element EES showed similar and sustained results in terms of safety and efficacy for treating a broad population of all-comers." @default.
• W2792740135 created "2018-03-29" @default.
• W2792740135 creator A5005157305 @default.
• W2792740135 creator A5006183199 @default.
• W2792740135 creator A5019137844 @default.
• W2792740135 creator A5019960871 @default.
• W2792740135 creator A5025617105 @default.
• W2792740135 creator A5031934775 @default.
• W2792740135 creator A5032047024 @default.
• W2792740135 creator A5033855482 @default.
• W2792740135 creator A5034235902 @default.
• W2792740135 creator A5034680904 @default.
• W2792740135 creator A5036459841 @default.
• W2792740135 creator A5036599056 @default.
• W2792740135 creator A5038626392 @default.
• W2792740135 creator A5058093407 @default.
• W2792740135 creator A5062318295 @default.
• W2792740135 creator A5069983884 @default.
• W2792740135 creator A5083182600 @default.
• W2792740135 date "2018-03-01" @default.
• W2792740135 modified "2023-09-26" @default.
• W2792740135 title "5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents" @default.
• W2792740135 cites W1212302497 @default.
• W2792740135 cites W141587258 @default.
• W2792740135 cites W1482348910 @default.
• W2792740135 cites W1556405519 @default.
• W2792740135 cites W1921048136 @default.
• W2792740135 cites W1938141958 @default.
• W2792740135 cites W2055057362 @default.
• W2792740135 cites W2085920974 @default.
• W2792740135 cites W2087150869 @default.
• W2792740135 cites W2129834146 @default.
• W2792740135 cites W2143178796 @default.
• W2792740135 cites W2143566938 @default.
• W2792740135 cites W2157330827 @default.
• W2792740135 cites W2160030867 @default.
• W2792740135 cites W2238136941 @default.
• W2792740135 cites W2284849554 @default.
• W2792740135 cites W2307015938 @default.
• W2792740135 cites W2548177476 @default.
• W2792740135 cites W2576257404 @default.
• W2792740135 cites W2577327103 @default.
• W2792740135 cites W2580212232 @default.
• W2792740135 cites W2580444586 @default.
• W2792740135 cites W2620950555 @default.
• W2792740135 cites W2749851477 @default.
• W2792740135 cites W4236805817 @default.
• W2792740135 doi "https://doi.org/10.1016/j.jcin.2017.11.031" @default.
• W2792740135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29519378" @default.
• W2792740135 hasPublicationYear "2018" @default.
• W2792740135 type Work @default.
• W2792740135 sameAs 2792740135 @default.
• W2792740135 citedByCount "38" @default.
• W2792740135 countsByYear W27927401352018 @default.
• W2792740135 countsByYear W27927401352019 @default.
• W2792740135 countsByYear W27927401352020 @default.
• W2792740135 countsByYear W27927401352021 @default.
• W2792740135 countsByYear W27927401352022 @default.
• W2792740135 countsByYear W27927401352023 @default.
• W2792740135 crossrefType "journal-article" @default.
• W2792740135 hasAuthorship W2792740135A5005157305 @default.
• W2792740135 hasAuthorship W2792740135A5006183199 @default.
• W2792740135 hasAuthorship W2792740135A5019137844 @default.
• W2792740135 hasAuthorship W2792740135A5019960871 @default.
• W2792740135 hasAuthorship W2792740135A5025617105 @default.
• W2792740135 hasAuthorship W2792740135A5031934775 @default.
• W2792740135 hasAuthorship W2792740135A5032047024 @default.
• W2792740135 hasAuthorship W2792740135A5033855482 @default.
• W2792740135 hasAuthorship W2792740135A5034235902 @default.
• W2792740135 hasAuthorship W2792740135A5034680904 @default.
• W2792740135 hasAuthorship W2792740135A5036459841 @default.
• W2792740135 hasAuthorship W2792740135A5036599056 @default.
• W2792740135 hasAuthorship W2792740135A5038626392 @default.
• W2792740135 hasAuthorship W2792740135A5058093407 @default.
• W2792740135 hasAuthorship W2792740135A5062318295 @default.
• W2792740135 hasAuthorship W2792740135A5069983884 @default.
• W2792740135 hasAuthorship W2792740135A5083182600 @default.
• W2792740135 hasBestOaLocation W27927401351 @default.
• W2792740135 hasConcept C126322002 @default.
• W2792740135 hasConcept C141071460 @default.
• W2792740135 hasConcept C164705383 @default.
• W2792740135 hasConcept C168563851 @default.
• W2792740135 hasConcept C203092338 @default.
• W2792740135 hasConcept C2777546689 @default.
• W2792740135 hasConcept C2778583881 @default.
• W2792740135 hasConcept C2780400711 @default.
• W2792740135 hasConcept C2780797203 @default.
• W2792740135 hasConcept C2908647359 @default.
• W2792740135 hasConcept C500558357 @default.
• W2792740135 hasConcept C71924100 @default.
• W2792740135 hasConcept C99454951 @default.
• W2792740135 hasConceptScore W2792740135C126322002 @default.
• W2792740135 hasConceptScore W2792740135C141071460 @default.
• W2792740135 hasConceptScore W2792740135C164705383 @default.
• W2792740135 hasConceptScore W2792740135C168563851 @default.
• W2792740135 hasConceptScore W2792740135C203092338 @default.
• W2792740135 hasConceptScore W2792740135C2777546689 @default.
• W2792740135 hasConceptScore W2792740135C2778583881 @default.

• next